The recently announced agreements in Asia brings further external validation of MOB-015 as a promising new topical treatment of onychomycosis, boosting our conviction about the case ahead of the first top-line results expected in December. The share price has performed strongly in 2019 (+78%), but we see further upside for the stock before the top-line results.